Sonya Craig1, Ilias Kylintireas2, Malcolm Kohler3, Debby Nicoll1, Daniel J Bratton3,4, Andrew J Nunn4, Paul Leeson5, Stefan Neubauer2, John R Stradling1. 1. Oxford Centre for Respiratory Medicine, Oxford Biomedical Research Centre and Oxford University, Oxford, UK. 2. Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 3. Sleep Unit Disorders Center and Pulmonary Division University Hospital Zurich, Zurich, Switzerland. 4. Medical Research Council Clinical Trials Unit at University College London, London, UK. 5. Oxford Cardiovascular Clinical Research Facility, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Abstract
STUDY OBJECTIVES: Minimally symptomatic obstructive sleep apnea (OSA) is highly prevalent, and the effects of continuous positive airway pressure (CPAP) on myocardial function in these patients are unknown. The MOSAIC randomized, controlled trial of CPAP for minimally symptomatic OSA assessed the effect of CPAP on myocardial function in a subset of patients. METHODS: Two centers taking part in the MOSAIC trial randomized 238 patients in parallel to 6 months of CPAP (120) or standard care (118). Of these, 168 patients had echocardiograms, and 68 patients had a cardiac magnetic resonance scan (CMR). A larger group (314) from 4 centers had brain natriuretic peptide (BNP) measured. RESULTS: Mean (SD) baseline oxygen desaturation index (ODI) and Epworth sleepiness score (ESS) were 13.5 (13.2), and 8.4 (4.0), respectively. CPAP significantly reduced ESS and ODI. Baseline LV ejection fraction (LVEF) was well preserved (60.4%). CPAP had no significant effect on echo-derived left atrial (LA) area (-1.0 cm2, 95% CI -2.6 to +0.6, p = 0.23) or early to late left ventricular filling velocity (E/A) ratio (-0.01, 95% CI -0.07 to +0.05, p = 0.79). There was a small change in echo-derived LV end diastolic volume (EDV) with CPAP (-5.9 mL, 95% CI -10.6 to -1.2, p = 0.015). No significant changes were detected by CMR on LV mass index (+1.1 g/m(2), 95% CI -5.9 to +8.0, p = 0.76) or LVEF (+0.8%, 95% CI -1.2 to +2.8, p = 0.41). CPAP did not affect BNP levels (p = 0.16). CONCLUSIONS: Six months of CPAP therapy does not change cardiac functional or structural parameters measured by echocardiogram or CMR in patients with minimally symptomatic mild-to-moderate OSA. CLINICAL TRIAL REGISTRATION: ISRCTN 34164388 (http://isrctn.org).
STUDY OBJECTIVES: Minimally symptomatic obstructive sleep apnea (OSA) is highly prevalent, and the effects of continuous positive airway pressure (CPAP) on myocardial function in these patients are unknown. The MOSAIC randomized, controlled trial of CPAP for minimally symptomatic OSA assessed the effect of CPAP on myocardial function in a subset of patients. METHODS: Two centers taking part in the MOSAIC trial randomized 238 patients in parallel to 6 months of CPAP (120) or standard care (118). Of these, 168 patients had echocardiograms, and 68 patients had a cardiac magnetic resonance scan (CMR). A larger group (314) from 4 centers had brain natriuretic peptide (BNP) measured. RESULTS: Mean (SD) baseline oxygen desaturation index (ODI) and Epworth sleepiness score (ESS) were 13.5 (13.2), and 8.4 (4.0), respectively. CPAP significantly reduced ESS and ODI. Baseline LV ejection fraction (LVEF) was well preserved (60.4%). CPAP had no significant effect on echo-derived left atrial (LA) area (-1.0 cm2, 95% CI -2.6 to +0.6, p = 0.23) or early to late left ventricular filling velocity (E/A) ratio (-0.01, 95% CI -0.07 to +0.05, p = 0.79). There was a small change in echo-derived LV end diastolic volume (EDV) with CPAP (-5.9 mL, 95% CI -10.6 to -1.2, p = 0.015). No significant changes were detected by CMR on LV mass index (+1.1 g/m(2), 95% CI -5.9 to +8.0, p = 0.76) or LVEF (+0.8%, 95% CI -1.2 to +2.8, p = 0.41). CPAP did not affect BNP levels (p = 0.16). CONCLUSIONS: Six months of CPAP therapy does not change cardiac functional or structural parameters measured by echocardiogram or CMR in patients with minimally symptomatic mild-to-moderate OSA. CLINICAL TRIAL REGISTRATION: ISRCTN 34164388 (http://isrctn.org).
Authors: Miguel A Arias; Francisco García-Río; Alberto Alonso-Fernández; Olga Mediano; Isabel Martínez; José Villamor Journal: Circulation Date: 2005-07-11 Impact factor: 29.690
Authors: Carmen Carmona-Bernal; Esther Quintana-Gallego; Manuel Villa-Gil; Angeles Sánchez-Armengol; Angel Martínez-Martínez; Francisco Capote Journal: Chest Date: 2005-05 Impact factor: 9.410
Authors: Apoor S Gami; Gregg Pressman; Sean M Caples; Ravi Kanagala; Joseph J Gard; Diane E Davison; Joseph F Malouf; Naser M Ammash; Paul A Friedman; Virend K Somers Journal: Circulation Date: 2004-07-12 Impact factor: 29.690
Authors: Luciano F Drager; Luiz A Bortolotto; Adelaide C Figueiredo; Bruno Caldin Silva; Eduardo M Krieger; Geraldo Lorenzi-Filho Journal: Chest Date: 2007-05 Impact factor: 9.410
Authors: Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod Journal: J Clin Sleep Med Date: 2019-02-15 Impact factor: 4.062
Authors: Jessie P Bakker; Dimitrios Baltzis; Francesco Tecilazich; Raymond H Chan; Warren J Manning; Tomas G Neilan; Meredith L Wallace; Margo Hudson; Atul Malhotra; Sanjay R Patel; Aristidis Veves Journal: Ann Am Thorac Soc Date: 2020-04
Authors: Christian Schlatzer; Daniel J Bratton; Sonja E Craig; Malcolm Kohler; John R Stradling Journal: BMJ Open Date: 2016-03-16 Impact factor: 2.692
Authors: Stefan Mihaicuta; Lucreţia Udrescu; Mihai Udrescu; Izabella-Anita Toth; Alexandru Topîrceanu; Roxana Pleavă; Carmen Ardelean Journal: Diagnostics (Basel) Date: 2021-01-07